Deutsche Says Anacor (ANAC) Tavaborole Numbers are Solid, Hinges on 2nd Phase 3 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Canaccord Genuity Trims PT on Anacor Pharmaceuticals (ANAC), Keeps Buy
January 30, 2013 10:09 AM ESTCanaccord Genuity lowered its price target on Anacor Pharmaceuticals (NASDAQ: ANAC) from $9 to $5 but is keeping a Buy rating following phase 3 data on Tavaborole.
The firm comments, "Maintaining BUY but lowering target to $5 from $9 as tavaboroles potential in onychomycosis becomes... More
Anacor Pharma (ANAC) Reports Positive P-3 Data on Tavaborole for Onychomycosis
January 29, 2013 7:10 AM ESTAnacor Pharmaceuticals (NASDAQ: ANAC) today announced positive preliminary results from the first of two Phase 3 trials of tavaborole, its topical anti-fungal for onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States. Tavaborole achieved a high... More
